Arecor Therapeutics PLC ARECOR ANNOUNCES PRESENTATION AT EASD 2022
July 04 2022 - 2:00AM
RNS Non-Regulatory
TIDMAREC
Arecor Therapeutics PLC
04 July 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR ANNOUNCES PRESENTATION AT EASD 2022 OF
PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID
ACTING INSULIN FOR DIABETES
Cambridge, UK , 4 July 2022: Arecor Therapeutics plc (AIM:
AREC), a globally focused biopharmaceutical company advancing
today's therapies to enable healthier lives, today announces that
its abstract titled " Phase I study investigating PK and PD of
highly-concentrated insulin aspart AT278 U500 " has been selected
for presentation as part of the Short Oral Discussion Session A at
the 58(th) Annual Meeting of the European Association for the Study
of Diabetes ( EASD ) meeting, which will be held from 19-23
September 2022 in Stockholm, Sweden and online.
The presentation will take place on Tuesday 20 September during
the SO 19 Short Oral Discussion Session " How complicated is type 1
diabetes? " (11:45-12:45)
Oral Presentation: Phase I study investigating PK and PD of
highly-concentrated insulin aspart AT278 U500
Presenting Author: Dr Eva Svehlikova
Presentation Number: 407
Date and Time: Tuesday, 20 September 2022, between 11:45 and
12:45 (Central European Time)
AT278 is an ultra-concentrated (500U/mL) novel formulation of
insulin that has been designed to significantly accelerate insulin
absorption post injection to enable more effective and convenient
management of blood glucose levels in people with high daily
insulin requirements.
Sarah Howell, Chief Executive Officer at Arecor, said : "AT278
has the potential to be the first, and potentially only,
ultra-concentrated (500U/mL) yet ultra-rapid acting insulin. This
product offers the potential to significantly improve post prandial
control whilst also reducing the injection volume and number of
daily injections for the growing population of people living with
diabetes who have high daily insulin needs, particularly those with
type 2 diabetes. In addition, with its unique profile, AT278 is a
key enabler in the development of next generation miniaturised
insulin delivery devices, an expected future disrupter in the
market. We look forward to sharing our ground-breaking data for
this next generation insulin candidate with scientific colleagues
in Stockholm and around the world."
About the EASD
The European Association for the Study of Diabetes (EASD) is a
non-profit, medical scientific association, founded in 1965 to
encourage and support research in the field of diabetes, the rapid
diffusion of acquired knowledge and to facilitate its application.
EASD holds its Annual Meeting in a different European city each
year with more than 15,000 delegates from over 130 countries
attending. The scientific programme includes more than 1,200 talks
and presentations on the latest results in diabetes research by
leading experts in the field
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
About AT278
AT278 is Arecor's ultra-concentrated, ultra-rapid acting insulin
designed to accelerate the absorption of insulin post injection, to
enable more effective management of blood glucose levels to the
increasing number of people with diabetes with high daily insulin
requirements (>200 units/day), whilst maintaining the
convenience and compliance benefits of being able to deliver these
high insulin doses in a lower injection volume via a single
injection. A truly rapid acting concentrated insulin is a critical
step towards the advancement and miniaturisation of the next
generation of insulin delivery devices.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABKNBKCBKDOOK
(END) Dow Jones Newswires
July 04, 2022 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024